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In a search of new, small leucine-rich repeat proteoglycan/
protein (SLRP) family members, a novel gene, nephrocan
(NPN), has been identified. The gene consists of three exons,
and based on the deduced amino acid sequence, NPN has 17
leucine-rich repeat motifs and unique cysteine-rich clusters
both in the N and C termini, indicating that this gene belongs to
a new class of SLRP family. NPN mRNA was predominantly
expressed in kidney in adult mice, and during mouse embryo-
genesis, the expression was markedly increased in 11-day-old
embryos at a time when early kidney development takes place.
In the adult mouse kidney, NPN protein was located in distal
tubules and collecting ducts. When NPN was overexpressed in
cell culture, the protein was detected in the cultured medium,
and upon treatment with N-glycosidase F, the molecular mass
was lowered by 14 kDa, indicating that NPN is a secreted
N-glycosylated protein. Furthermore, transforming growth fac-
tor- (TGF-)-responsive 3TP promoter luciferase activity was
down-regulated, and TGF--induced Smad3 phosphorylation
was also inhibited by NPN, suggesting that NPN suppresses
TGF-/Smad signaling.Taken together,NPN is anovelmember
of the SLRP family that may play important roles in kidney
development and pathophysiology by functioning as an endog-
enous inhibitor of TGF- signaling.
Leucine-rich repeat (LRR)2 is a highly conserved motif from
bacteria tomammals, and LRR proteins have diverse structural,
biological, and cellular functions such as matrix organization,
host defense, inflammation, and cell death (1–3). LRR is com-
posed of 20–29 amino acid residues rich in hydrophobic amino
acids such as leucine, isoleucine, and valine. Recently, the three-
dimensional structures of several LRR proteins such as human
ribonuclease inhibitor, light chain1 of dynein, plague virulence
protein, YopM, etc. have been determined (4–6), and all of the
structures reported have significant similarities forming a
curved shape with a parallel -sheet on the concave side and
helical elements primarily on the convex side. This specific
structure has been thought to be a conformation ideal for bind-
ing to other proteins (5). In addition, recent structural studies
on LRR proteins support the characteristic horseshoe structure
(7, 8) with more variations (9).
Small leucine-rich proteoglycans/proteins (SLRPs) are an
evolutionally conserved family of secreted proteins that are
synthesized as a small core protein containing 6–20 LRRmotifs
and post-translationally modified with glycosaminoglycan
chain(s), N-glycosylation, and/or tyrosine sulfation (10). It has
been suggested that SLRP familymembers play important roles
in collagen fibrillogenesis, cellular proliferation, cell differenti-
ation, andmigration in various tissues (11, 12). They are divided
into several subclasses depending on numbers of exons,
interspaced amino acidswithin theN-terminal cysteine cluster,
and LRR motifs. Decorin (DCN), a prototype member of the
SLRP family, belongs to class I and is composed of a character-
istic N-terminal cysteine cluster (CX3CXCX6C), a central
region containing 10 LRR motifs, and a C-terminal cysteine
cluster. DCN is ubiquitously expressed, and it has been exten-
sively characterized as a collagen-binding protein (13–17)
modulating collagen fibrillogenesis (18, 19). DCN has also been
shown to inhibit cell growth as a putative tumor suppressor (20,
21) and to bind to transforming growth factor- (TGF-) as a
regulator of growth factor functions (22, 23). At present, 15
SLRP members have been cloned and partially character-
ized, and most are located in clusters on human and mouse
chromosome (24).
Here we present a newmember of the SLRP family identified
by a bioinformatics approach using DCN as a query protein
sequence. Because this protein appears to be specifically
expressed in kidney, it is named as “nephrocan (NPN)”. Its gene
structure, mRNA expression pattern, distribution, cellular
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localization, effects on TGF- activity, and potential functions
are described in this study.
EXPERIMENTAL PROCEDURES
Cell Culture—Human embryonic kidney 293 cells were pur-
chased from Clontech and maintained in Dulbecco’s modified
Eagle’smedium (Invitrogen) containing a high concentration of
glucose (4.5 mg/ml), supplemented with 10% fetal bovine
serum (Sigma), 100 units/ml penicillin, and 100 g/ml strepto-
mycin in a 5% CO2 atmosphere at 37 °C.
MolecularCloning ofMouseNephrocan cDNA—To identify a
new member of the SLRP family, we first obtained the oreo-
chromis niloticus (nile tilapia) ortholog of DCN (GenBankTM
accession number; AF247822) as a query protein sequence and
performed a BLAST search of the mouse genome. The candi-
date sequences were then obtained, and the PSORT II program
was used to predict the subcellular localization. This computa-
tional screening identified a probable extracellular molecule,
NPN, that has a signal peptide sequence but lacks a transmem-
brane domain.Nextwe searched its tissue distribution based on
the expressed sequence tags (EST) data base sequences.
According to that computational information, NPN mRNA
was expressed in kidney (EST sequence numbers CA468708.1,
AW611331.1, and BX512695.1), aorta (BB224812.1 and
BB223005.1), pancreas (BM055738.1), and 8-day-old embryos
(AV311419.1). The cDNA derived from kidney was therefore
used as a template. The cDNAs containing the coding sequence
of NPN were isolated by RT-PCR using Hotstar TaqDNA po-
lymerase (Qiagen). The sequences of the primers were as fol-
lows: forward primer, 5-GCAATGCACCCGCTTTGGGCT-
TTTC-3, and reverse primer, 5-ATCTATTTCATAATCGT-
CATCGTCGTC-3. The PCRproduct was then ligated into the
pcDNA3.1-V5/His-TOPO mammalian expression vector
(Invitrogen), sequenced at the University of North Carolina
at Chapel Hill, DNA Sequencing Facility, and the DNA
sequence was 100% identical with the one deposited in the
public source (NCBI reference sequence numberNM_025684).
The coding sequence ofNPNwas then subcloned into pcDNA3
fused with hemagglutinin (HA) tag vector (kindly provided
by Dr. H. Ichijo, University of Tokyo, Japan) and the
pcDNA3.1-V5/His-TOPO mammalian expression vector and
sequenced (pcDNA3-NPN-HA and pcDNA3.1-NPN-V5/His).
The sequences including 5- and 3-untranslated regions were
also amplified with the forward primer, 5-TGCTTGCTACT-
TGCAAAC-3, and reverse primer, 5-GCCTAAGTTTCAG-
ACTAAAACACAAC-3. The PCR product was ligated into
pCR 2.1-TOPO vector (Invitrogen) and sequenced.
Tissue Distribution Determined by RT-PCR and Real Time
PCR—RT-PCR was performed using the mouse MTC panel I
(BDBiosciences) containing cDNAof heart, brain, spleen, lung,
liver, skeletal muscle, kidney, testis, 7-, 11-, 15-, and 17-day-old
embryo as templates. The sequences of primers for NPN were
designed as follows: forward primer, 5-CAGAATCTGCTGT-
TGTCTATCCCTC-3 and reverse primer, 5-CACACTTGT-
GCTTAAGACAGTGGAC-3. RT-PCR using glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) control primers
provided with the MTC panel I was also performed with the
same templates. The PCR conditions were as follows: 15 min at
95 °C, 30 s at 95 °C, and 3min at 68 °C for 38 cycles (NPN) or for
22 cycles (GAPDH). The PCR products amplified byNPN or by
GAPDH primers were analyzed on a 1.2% agarose gel.
To quantitatively analyze the expression levels of NPN, ali-
quots of cDNA of mouse MTC panel I were also used as tem-
plates for NPN (ABI assay number Mm00481816_m1) or
GAPDH (ABI assay number 4308313). Real time PCR was per-
formed in triplicate using the ABI Prism 7000 sequence detec-
tion system (Applied Biosystems). The mean fold changes in
the expression of NPN relative to that of GAPDH were calcu-
lated using the values of the expression of eithermouse heart or
7-day-old embryo cDNA as a calibrator by means of 2CT
method as described previously (25).
Generation and Characterization of Anti-NPN Antibody—A
polyclonal NPN antibodywas generated by immunizing rabbits
with a synthetic peptide corresponding to the sequence in the
4th LRR region of NPN, i.e. 112SALPANLEVLKLNDNAIC129
(Alpha Diagnostic International Inc., San Antonio, TX). Both
preimmune serum and anti-NPN polyclonal antibody were
then further affinity-purified with ImmunoPure (A Plus) IgG
purification kit (Pierce) andused forWestern blot analyses. The
heart, lung, liver, brain, and kidney tissues obtained from Har-
lan Sprague-Dawley mice (8–12 weeks) were pulverized and
then extracted with 6 M guanidine-HCl, pH 7.4, for 2 days at
4 °C, and the supernatants were separated from the insoluble
residues by centrifugation (15,000  g) for 30 min, dialyzed
against distilled water, and lyophilized. Aliquots of dried sam-
ples were dissolved in lysis buffer containing 150 mM NaCl, 20
mM Tris-HCl, pH 7.5, 10 mM EDTA, 1% Triton X-100, 1%
sodium deoxycholate, 1.5% aprotinin, and 1mM phenylmethyl-
sulfonyl fluoride and centrifuged, and the protein concentra-
tions in the supernatants were measured by a platereader using
a DC protein assay kit (Bio-Rad). The samples with equal
amounts of proteins were then subjected toWestern blot anal-
ysis with anti-NPN antibody, preimmune serum, or anti-V5
antibody (Invitrogen) as described below.
Purification of NPN-V5/His Fusion Protein—pcDNA3.1-
NPN-V5/His vector was transfected into 293 cells using
FuGENE 6 transfection reagent (Roche Diagnostics) according
to the manufacturer’s instructions, and the cells were cultured
in the presence of 400 g/ml of G418 (Invitrogen) for 3–4
weeks to select stably transfected clones. Positive clones
derived fromG418-resistant cells were then isolated by cloning
rings and further grown in the same conditions. Equal numbers
of cells in each clone were plated onto 6-well culture plates at a
density of 3  105cells/well and cultured for 3 days. Cultured
media were then collected and subjected toWestern blot anal-
yses with anti-V5 antibody to assess the NPN-V5/His protein
levels synthesized by the clones. The clone that synthesized the
highest level of NPN-V5/His protein was further cultured for 6
days, and the cultured medium was collected. NPN-V5/His
fusion protein was purified using a nickel-nitrilotriacetic acid-
agarose resin (Qiagen), and purified proteins were pooled, dia-
lyzed against distilled water, lyophilized, and kept at 20 °C
until use. To determine the purity of NPN-V5/His protein, ali-
quots of the dried samples were dissolved in distilled water, and
protein concentration was measured using a DC protein assay
kit (50 ng/l), solubilized in SDS sample buffer (100mMTris-
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HCl, pH 8.8, 0.01% bromphenol blue, 36% glycerol, 4% SDS) in
the presence of 10 mM dithiothreitol, and separated by 4–12%
SDS-PAGE. The samples were analyzed by Coomassie Brilliant
Blue R-250 staining andWestern blotting using anti-NPN anti-
body or anti-V5 antibody as described below.
Immunohistochemistry—To determine the distribution of
NPN within kidney, immunohistochemical staining was per-
formed using Vectastain Elite ABC kit (Vector Laboratories
Inc.). Formalin-fixed paraffin-embedded sections of nondis-
eased control adult mouse kidney or liver were deparaffinized
with xylene and graded ethanol and treated with 20 g/ml pro-
teinase K (Roche Diagnostics) for 10 min. The sections were
then incubated with 0.3% H2O2 in methanol for 30 min, fol-
lowed by incubation with anti-NPN antibody (diluted in 1:200)
overnight at 4 °C.Afterwashingwith phosphate-buffered saline
(PBS) several times, sections were further incubated with bio-
tinylated IgG for 20 min and subsequently with avidin and bio-
tinylated horseradish peroxidase for 20 min. Following several
washeswith PBS, 3,3- diaminobenzidine nickel substrate (Vec-
tor Laboratories Inc.) was applied, and the sections were also
counterstained with hematoxylin (Sigma).
To verify the specificity of the anti-NPN antibody, the effect
of the synthetic peptide used for immunization on the immu-
noreactivity was evaluated. The anti-NPN antibody with or
without the synthetic peptide was incubated overnight at 4 °C
and subjected to immunostaining in the same manner as
describe above. Purified preimmune serum described above
was used as a negative control. The immunoreactivities of spec-
imens visualized were photographed under a light microscope
(Nikon-FXA) at a magnification of 20.
Immunoprecipitation andWestern Blot Analysis—To exam-
ine the subcellular localization of NPN, 293 cells were plated
onto 6-well culture plates at a density of 3  105 cells/well,
and on the following day, the cells were transfected with
an empty pcDNA3.1-V5/His A vector (Invitrogen) or
pcDNA3.1-NPN-V5/His vector using FuGENE 6 transfec-
tion reagent. After 72 h, the cultured medium was collected,
and the transfected cells were washed with PBS and lysed
with the lysis buffer. The cultured medium and the lysate
were then incubated with anti-V5 antibody. After addition of
protein A-Sepharose 4B conjugate (Zymed Laboratories
Inc.), the samples were incubated for an additional 30 min,
and the beads were washed twice with the lysis buffer, solu-
bilized in SDS sample buffer in the presence of 10 mM dithi-
othreitol, and separated by 4–12% SDS-PAGE. The proteins
were transferred to a polyvinylidene fluoride membrane
(Immobilon-P; Millipore), reacted with anti-V5 antibody,
and detected by alkaline phosphatase conjugate substrate kit
(Bio-Rad). As for Smad3 phosphorylation, 293 cells were
treated with 10 ng/ml of human TGF-1 (R&D Systems)
with or without purified NPN-V5/His fusion protein and
incubated for 24 h. Cell lysate was used for Western blotting
with anti-phospho-Smad3 antibody (BIOSOURCE). Equal
protein loading was confirmed using anti-actin antibody
(Sigma). Three independent experiments were performed,
and the results were essentially identical.
N-Glycosylation Analysis—To examine whether or not NPN
is N-glycosylated, 293 cells were plated onto 6-well culture
plates at a density of 3  105 cells/well and transfected with the
pcDNA3.1-NPN-V5/His vector. After 72 h, the cultured
medium was immunoprecipitated with anti-V5 antibody, and
the immunocomplex was collected using protein A-Sepharose
beads. Aliquots of the samples were then treated withN-glyco-
sidase F enzyme (Prozyme Inc., San Leandro, CA) for 24 h at
37 °C, subjected toWestern blot analysis in the samemanner as
described above, and compared with the untreated samples.
Luciferase Assay—293 cells were transiently transfected with a
combinationof the followingvectors: 3TP luciferase reporterplas-
mid vector, Renilla expression vector pRL-TK, NPN expression
vectors (pcDNA3-NPN-HA or pcDNA3.1-NPN-V5/His). Cells
were treated with 10 ng/ml human TGF-1, and the luciferase
activities in the cell lysates were determined using the dual
reporter assay system (Promega). The firefly luciferase activities
were then normalized to theRenilla luciferase activities under the
control of thymidine kinase promoter. Furthermore, after the
transfection of 3TP luciferase and Renilla vectors, TGF-1 was
added together with purified NPN-V5/His fusion protein (50
ng/l), and the luciferase activities were measured in the same
manner. All of the luciferase experiments were performed in
triplicate.
RESULTS
NPN Belongs to a New Class of the SLRP Family—Based on
the predicted amino acid sequences, NPN is a 512-amino acid-
long protein and shares some structural characteristics with
other SLRP members, i.e. it has a putative signal peptide
sequence, a characteristic cysteine cluster (CX3CXCX7C) in the
N terminus (Fig. 1A), 17 LRRmotifs (Fig. 1B), and 3 exons (Fig.
1C). However, NPN has several features distinct from other
SLRP members, including four cysteine residues in the C-ter-
minal flanking domain, five potentialN-glycosylation sites, and
a polyacidic amino acid tail (DDDDDDYEID) at the C terminus
(Fig. 1A). Characterization of the LRR motif was based on the
general consensus sequence (2, 26, 27) for type T (zzxx-
axxxxFxxaxxLxxLxLxxNxL) and type S (xxaPzxLPxxLxxLx-
LxxNxI). In both types of LRRmotifs, “z” is frequently a gap; “x”
indicates variable residues; “a” is valine, leucine, or isoleucine;
and I is isoleucine or leucine. In NPN, of 17 LRR motifs, there
are 11 type T and 6 type S present (Fig. 1B). Based on these
criteria (27), class I and II SLRPs have 12 LRRmotifs composed
of four tandem STT “super-motifs,”, i.e. (STT)4. Class III
SLRPs, including epiphycan and osteoglycin, have 7 LRRs com-
posed of (ST)T(ST)2. Chondroadherin, a representative of class
IV member, contains 10 type T LRRs. Although the conserved
asparagine residues of LRR1 and LRR2 in NPN are substituted
with serine (LRR1) and glutamic acid (LRR2), the organization
of LRRs in NPN is unique, i.e. (STT)2ST(STT)3. The NPN gene
is localized on mouse chromosome locus 10 in silico and spans
over 1.4 kbp (Fig. 1C). Phylogenetic tree analysis of NPN
together with the known SLRP members was performed using
the ClustalW server and ClustalX program (28) (Fig. 1D). The
mouse protein sequences used in this studywere obtained from
the public data base deposited as NCBI reference sequences.
These results indicate that NPN belongs to a new class of the
SLRP family (2, 10, 12, 26, 27).
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Tissue Distribution of NPN—To determine the tissue distri-
bution of NPN mRNA expression, both RT-PCR and real time
PCR analyses were performed. As shown in Fig. 2A, the band
amplified using NPN-specific primers was clearly detected in
adult kidney and, to a much lesser extent, in heart, lung, and
skeletal muscle. The expression was undetectable in all other
tissues. Using the cDNAofmouse embryos at various stages, its
expression was found to be tran-
siently up-regulated at day 11 and
decreased thereafter.
To quantify the levels of NPN
mRNA expression among the tis-
sues tested, real time PCR analysis
was performed. The results also
demonstrated that the expression
level in kidney was the highest (6-
fold of that in heart) among the tis-
sues tested in adult mice, and that
during the embryonic development,
the expression was highest at day 11
(2-fold of that in embryonic day
7), a time critical for kidney devel-
opment (29) (Fig. 2B). The results
were further confirmed by analyz-
ing another set of mouse MTC
panel I (data not shown).
Localization of NPN Protein—To
determine the tissue distribution of
NPNprotein, an anti-NPNantibody
was generated, and its specificity
was characterized. To confirm the
NPN-V5/His protein was purified,
the protein was stained by Coomas-
sie Brilliant Blue R-250 (Fig. 3A,
lane 2), and a single band was
observed at the expected molecular
weight size. The same protein was
further analyzed by Western blot-
ting using anti-NPN antibody and
anti-V5 antibody (Fig. 3A, lanes 1
and 3), and it was immunoreactive
to both antibodies. Because the
epitope for the former resides in
the N-terminal region of NPN, and
the V5 tag was fused to the C termi-
nus of NPN, these results demon-
strate that the full-length NPN-V5/
His protein was successfully
purified (Fig. 3A) and that anti-NPN
antibody recognizes NPN. The tis-
sue distribution of NPN was then
examined by Western blot analysis
with this antibody using the protein
lysates derived from heart, lung,
liver, brain, and kidney. The puri-
fied NPN-V5/His fusion protein
was used as a positive control. The
results demonstrated that the
endogenous NPN protein (an 70-kDa band in Fig. 3B) was
detected in kidney and, to a lesser extent, in heart and lung but
not in liver and brain (Fig. 3B, left panel, lanes 1–5). The immu-
noreactive bands were observed as a doublet in kidney possibly
because of the varied extent of post-translationalmodifications,
the presence of a splicing variant, or protein processing/degra-
dation (Fig. 3B, left panel, lane 5). This tissue distribution was
FIGURE 1. The amino acid sequence, gene structure, and phylogenetic analysis of nephrocan. A, the
deduced amino acid sequence of NPN. The putative signal peptide sequence and cleavage site (boxed in gray)
were predicted using the PSORT II program. Potential N-glycosylation sites (NX(S/T), where X is any amino acid)
are in boldface. The N-terminal cysteine cluster (CX3CXCX7C, where C is cysteine, and X is any amino acid) is
indicated by a dotted underline and C-terminal cysteine residues by double underlines. B, 17 LRR motifs aligned
based on the ClustalW program. A consensus sequence (Con.) is displayed below the alignments. The LRR
groups listed on the left represent type S LRR (xxaPzxLPxxLxxLxLxxNxI), and those on the right type T LRR
(zzxxaxxxxFxxaxxLxxLxLxxNxL, where x is variable residue; z is frequently a gap; a is valine, leucine, or isoleucine;
P is proline; N is asparatic acid; and I is isoleucine or leucine), respectively. C, the gene structure of NPN
consisting of three exons. D, phylogenetic tree analysis of NPN together with other mouse SLRP members.
PRELP is proline/arginine-rich end leucine-rich repeat protein; m-TSK is mouse ortholog of tsukushi (35).
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consistent with its mRNA expression pattern (Fig. 2). The puri-
fied NPN-V5/His fusion protein (pNPN) was detected at a
slightly higher molecular weight position likely because of the
presence of V5/His tag (5 kDa) (Fig. 3B, left panel, lane 6).
When Western blot analysis was done with either preimmune
serum or anti-V5 antibody, there were no immunoreactive
bands corresponding to the expected sizes in the tissue lysates
(Fig. 3B, middle panel, lanes 7–12, and right panel, lanes
13–17). An intense immunoreactive band was detected for
NPN-V5/His fusion protein when incubated with anti-V5 anti-
body (Fig. 3B, right panel, lane 18).
Using anti-NPN antibody we further examined the distribu-
tion of NPN protein in adult mouse kidney. As shown in Fig. 4,
the epithelial cells, but not fibroblasts, of distal tubules and
collecting ducts were extensively stained, and proximal epithe-
lial cells were slightly stained. There was no significant staining
in glomeruli (Fig. 4, A and C). In the presence of the synthetic
peptide together with anti-NPN antibody, the structures
described above were not immunostained, confirming the
specific immunolocalization of NPN (Fig. 4, B and D). Pre-
immune serum was also used as a negative control, and no
immunoreactivities were observed (Fig. 4E). No immunore-
activities were observed in liver where NPN gene expression
was not detected (Fig. 4F).
FIGURE 2. Tissue distribution of NPN. A, RT-PCR analysis with NPN-specific
primers or glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific
primers was performed. The PCR products were analyzed on 1.2% TAE-agar-
ose gel and photographed under UV light. Sk muscle, skeletal muscle. B, quan-
titative real time PCR analysis of NPN mRNA expression. The mean fold
changes in the expression of NPN relative to that of GAPDH were calculated
using the value of the expression of either heart or 7 day-embryo as a calibra-
tor. The values are shown as mean  S.D. based on triplicate assays. Sk mus-
cle; skeletal muscle.
FIGURE 3. Specificity of anti-NPN antibody (A) and distribution of NPN
protein in mouse adult tissues (B). A, purified NPN-V5/His fusion protein
(pNPN) was subjected to Western blot analysis with anti-NPN antibody
(lane 1) showing its immunoreactivity to pNPN. The purity of pNPN was
verified by Coomassie Brilliant Blue R-250 staining (lane 2) and Western
blot analysis with anti-V5 antibody (lane 3). The molecular weight of pNPN
and its immunoreactivity to both antibodies indicate that pNPN is a full-
length NPN. Markers of molecular mass are shown on the left. B, the pro-
teins extracted from heart, lung, liver, brain and kidney tissues were ana-
lyzed by Western blotting (WB) with anti-NPN antibody (left panel),
preimmune serum (middle panel), or anti-V5 antibody (right panel). NPN-
V5/His fusion protein (pNPN) was used as a positive control. Markers of
molecular mass are shown on the left.
FIGURE 4. Immunohistological detection of NPN in mouse adult kidney.
The mouse adult kidney sections were immunostained using anti-NPN anti-
body with (B and D) or without (A and C) the synthetic peptide used for anti-
body generation. The epithelial cells of distal tubules and collecting ducts
were extensively stained (A), and proximal epithelial cells were slightly
stained (C). There was no significant staining in glomeruli (C). The immunore-
activities were not observed using anti-NPN antibody in the presence of the
synthetic peptide (B and D). Preimmune serum was also used as a negative
control, and no immunoreactivities were observed (E). In liver, no immunore-
activities were observed (F). The specimens were observed and photo-
graphed under a light microscope at a magnification of 20.
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NPN Is a Secreted Glycoprotein—Because many SLRP family
members were secreted as proteoglycans with various types of
glycosaminoglycan chains, i.e. chondroitin/dermatan sulfate
(CS/DS) or keratan sulfate (10), we next determined whether
NPN is secreted in the extracellular space as predicted by the
PSORT II program and post-translationally modified. As
shown in Fig. 5, NPNwas detected only in the culturedmedium
fraction but not in the cell lysate, demonstrating that NPN is a
secreted protein (Fig. 5, lanes 3 and 6). The treatment with
chondroitinase ABC or endo--galactosidase did not change
the migration position of the NPN band on the gel, indicating
the absence of glycosaminoglycan chains in NPN (data not
shown). However, when treated withN-glycosidase F, the NPN
band was shifted from80 to66 kDa (Fig. 5, lane 4) confirm-
ing the presence of N-glycosylation in NPN as the amino acid
sequence suggested (Fig. 1A).
NPN Inhibits TGF-/Smad Signaling—It has been reported
that several SLRP members, including DCN, interact with a
number of growth factors such as TGF- (22, 23), platelet-de-
rived growth factor (30), and insulin-like growth factor-1 (31),
and modulate their activities. Because we have identified the
NPN gene based on the structural similarity to DCN, we inves-
tigated the possible regulatory function of NPN in TGF- sig-
naling. First, the effects of NPN on TGF--responsive lucifer-
ase promoter (3TP) activity were analyzed by overexpression or
exogenous addition of NPN. As shown in Fig. 6A, overexpres-
sion of NPN inhibited 3TP promoter activity in 293 cells, and
moreover, as shown in Fig. 6B, exogenous addition of NPN
protein inhibited the activity in a dose-dependentmanner. Sec-
ond, the effects of NPN on Smad3 phosphorylation were ana-
lyzed by TGF- stimulation with or without NPN (Fig. 6C) in
293 cells. Smad3 is a direct substrate of TGF- receptors and is
known to be phosphorylated upon TGF- stimulation. As
shown in Fig. 6C, NPN clearly
down-regulated the Smad3 phos-
phorylation, indicating that NPN
may function as an endogenous
inhibitor of the TGF-/Smad3 sig-
naling pathway, upstream of Smad3
phosphorylation.
DISCUSSION
Here we have reported identifica-
tion and partial characterization of a
new member of the SLRP family,
NPN. Itwas identified by employing a
bioinformatics approach based on its
structural similarity to DCN. DCN,
together with biglycan and asporin, is
a member of class I SLRP subfamily;
they all have eight exons in each gene,
identical numbers of interspaced
amino acids in the N-terminal cys-
teine cluster (CX3CXCX6C), and 10
LRRs in each core protein. BothDCN
and biglycan, but not asporin, usually
carry CS or DS glycosaminoglycan
chain(s). In comparison with these
characteristics of class I molecules,
NPN has several distinct features; its
gene has three exons, and the protein
contains uniquely interspaced amino
acids (CX3CXCX7C) in the N termi-
nus (residues 21–35) andhas 17LRRs
as shown in Fig. 1. In extracellular
FIGURE 5. NPN is a secreted glycoprotein. The 293 cells were transfected
with either an empty vector (EV or E) or pcDNA3.1-NPN-V5/His vector (NPN or
N). After the cultured medium (Medium) or cell lysate (Lysate) was collected,
the samples were immunoprecipitated (IP) with anti-V5 antibody (V5). The
immunocomplex was treated with or without N-glycosidase F and detected
by Western blotting (WB) using anti-V5 antibody. Markers of molecular mass
are shown on the left. Note that NPN was detected only in the cultured
medium fraction and not in the cell lysate, and the NPN band was shifted
upon N-glycosidase F treatment.
FIGURE 6. NPN inhibits TGF-/Smad signaling. A, overexpression of NPN inhibits TGF--responsive luciferase
activity. The 293 cells were transfected with an empty vector (), pcDNA3-NPN-HA vector (HA), or
pcDNA3.1-NPN-V5/His vector (V5) together with 3TP luciferase reporter plasmid and pRL-TK vectors. Cells were
treated with 10 ng/ml human TGF-1, and the luciferase activities in the cell lysates were measured. The values
indicated represent normalized luciferase activities and are shown as mean  S.D. based on assays done in
triplicate. B, the addition of NPN protein inhibits TGF--responsive luciferase activity in a dose-dependent
manner. The 293 cells were transfected with 3TP luciferase reporter plasmid and pRL-TK vectors and treated
with 10 ng/ml human TGF-1 and/or purified NPN-V5/His fusion protein (50 ng/l) as indicated. The lucifer-
ase activities were determined in the same manner as in A. C, NPN inhibits Smad3 phosphorylation induced by
TGF-. The 293 cells were treated with human TGF-1 with or without purified NPN-V5/His fusion protein, and
Western blotting (WB) was performed using anti-phospho-Smad3 antibody (anti-pSmad3). Equal protein load-
ing was confirmed using anti-actin antibody.
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proteins, LRRmotifs are often flanked by cysteine clusters at both
N-andC-terminaldomains.Themost commonC-terminal flank-
ing domain of SLRP members contains two cysteine residues (5);
however, NPN has four cysteine residues (Fig. 1A, indicated by
double underlines). In addition, class I SLRP members typically
contain a propeptide that may function as a recognition sequence
for xylosyltransferase that catalyzes the initial step of the biosyn-
thesis of CS or DS glycosaminoglycan chains (32). However, NPN
contains neither this conserved propeptide region nor serine-gly-
cine (SG) sequence required for the O-linked glycosaminoglycan
attachment. Therefore, NPN is likely not a proteoglycan but a gly-
coprotein (Fig. 5).According toNetNGlyc 1.0 Server program, the
potential for glycosylation for all five asparagine residues in NPN
was indeedabove threshold (0.5) (aminoacid66NFT68; poten-
tial 0.6848, 88 NDT 90; potential 0.5676, 256 NLS 258; potential
0.6271, 278 NLT 280; potential 0.6336, 428 NCT 430; and poten-
tial 0.5281, respectively). Some of the SLRPmembers, e.g. asporin
(33), osteoglycin (34), tsukushi (35), and podocan (36), are also
known to be glycoproteins but not proteoglycans.
Another unique motif found in NPN is a polyacidic tail
(DDDDDDYEID) at the C terminus. The tyrosine residue in
this sequence is likely sulfated, because it resides next to acidic
amino acids (37). The computational prediction using a Sulfi-
nator program (38) also supports this notion (E value) (52).
Therefore, an apparent molecular weight of NPN that is higher
than the expected value (58 kDa) (Figs. 3 and 5) is likely
because of those extensive post-translational modifications.
In our attempt to identify NPN homologs among different
species, putative NPN gene orthologs were found in pig (EST
sequence number BE015058.1), dog (NCBI reference sequence
number XM_541218), rat (NCBI reference sequence number
XM_228174), and chicken (NCBI reference sequence number
XM_426175), and interestingly, those are only conserved
among higher animals. In addition, we cloned and sequenced a
dog ortholog of NPN (GenBankTM accession number;
DQ233647) using the dog kidney cDNA (BioChain Institute,
Inc., Hayward, CA), and we found that the dog ortholog pos-
sesses a gene structure similar to that of mouse. At this point, it
is not clear if the human counterpart of NPN gene exists.
Although similar nucleotide sequences to mouse exon 2 and
exon 3 were identified (GenBankTM accession number
AL589939) in the human genomic cDNA library, exon 1 of
human was not identified. The possible reasons are as follows:
1) the exon 1 of the human counterpart may have lesser homol-
ogy with that of other animals, whichmakes the computational
search difficult; and 2) during evolution, this gene might have
become a pseudogene, accumulating mutations such as frame-
shifts, in-frame stop codons, or interspersed repeats in the orig-
inal protein-coding sequence (39). The latter is less likely
because the NPN gene appears to be well conserved among
higher animals as we identified NPN genes in both mouse and
dog. The search conditions may need to bemodified to identify
human NPN.
In the process of renal fibrosis, the trans-differentiation
process referred to as the epithelial-mesenchymal transition
(EMT), a processwhereby epithelial cells lose cell adhesion, and
the cell layers lose polarity and cell-cell contacts, is one of the
essential mechanisms. TGF- is a well characterized inducer of
EMT,and ithasbeenshownthat this transitionreliesonSmad3-
dependent transcription (40). It has been generally accepted
that TGF-, especially TGF-1 isoform, is a predominant cyto-
kine that causes renal fibrosis and plays an important role in the
pathological accumulation of extracellular matrix proteins and
degradation leading to kidney dysfunction (41). Interestingly, a
potential regulatory function of DCN in the progression of
renal fibrosis has been suggested. It has been demonstrated that
the administration of DCN in vivo can antagonize the action of
TGF- on the accumulation of pathological matrix proteins in
experimental kidney disease (42). However, DCN has been
shown to be present in many tissues and organs such as heart,
lung, liver, kidney, spleen, bone, and skin (43) and thus not
specific to kidney. The ability of NPN to inhibit the TGF-/
Smad3 signaling pathway raises the possibility that NPNmight
be another regulatory protein responsible for converting EMT
activities by TGF- and controlling matrix accumulation in
kidney. Interestingly, the transformation of mesenchyme to
epithelium (MET), the reverse of EMT, occurs during kidney
embryonic development. The cardinal feature of kidney devel-
opment is the formation of epithelial tubules from nonepithe-
lial mesenchymal cells. This conversion of cell type, MET, is
controlled by factors secreted from the ureteric bud (29, 44, 45)
at around embryonic day 10.5 to 11 in the mouse, and these
epithelial inducers have been purified from ureteric bud cell
lines (46) and show EMT converting activities in development
and in cell culture (47). In this study, we showed that NPN is
expressed in adult kidney. Moreover, NPN is up-regulated in
11-day-old embryo (Fig. 2B), a critical time forMET, suggesting
its importance in kidney development. It would be of interest to
investigate whether or not NPN is one of the endogenous epi-
thelial inducers secreted by the ureteric bud.
TGF- is known as a multifunctional growth factor with
potential effects on growth, differentiation, extracellularmatrix
accumulation, and the immune system. In kidney, it is known
that TGF- contributes to renal fibrosis (48). NPN protein in
adult mice kidney was mainly observed in distal tubules and
collecting ducts (Fig. 4, A and C), indicating those cells synthe-
size and/or uptakeNPNprotein. In particular, the expression of
NPN found in distal nephron is intriguing (Fig. 4). Fibrotic
change in this area is common in chronic renal disease, and the
pathology in the interstitium correlated with renal function.
Therefore, NPN, as a TGF- signaling inhibitor, may serve as
an anti-fibrotic function.
At this point, it is still unclear how NPN inhibits TGF-
signaling. TGF- is synthesized as a homodimeric proprotein,
and dimeric propeptide is intracellularly cleaved. TGF-
propeptide, called LAP, has high affinity to mature TGF-, and
this tight complex is secreted together with latent TGF--bind-
ing protein(s) as a large molecular weight complex (49). There-
fore, the dissociation from this complex is a central regulatory
mechanism for the activation of TGF-. Because the data dem-
onstrated that NPN is a secreted protein (Fig. 5), the inhibitory
effect(s) is likely through the extracellular interaction with the
following: 1) mature TGF- to inhibit the ligand-receptor(s)
complex; 2) LAP and/or latent TGF--binding proteins to form
a complex to inhibit the dissociation of mature TGF-; and/or
3) TGF- type I and/or type II receptor to block the binding of
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mature TGF- to its receptors. As it has been proposed that
DCN and other SLRP members modulate the activities of
TGF- superfamily, including bone morphogenetic proteins
(34, 35, 50), the results in this study further underscore critical
roles of SLRP members in controlling TGF- superfamily
signaling.
Given that the predominant expression of NPN is in kidney
and that it can inhibit the TGF-/Smad3 signaling pathway,
NPN could be an effective target molecule to prevent renal
fibrosis. Thus, further studies on the mechanisms by which
NPN inhibits TGF- activities may potentially lead to the
development of a strategy for the treatment of this disorder.
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